Cardiac-specific deletion of myostatin (a transforming growth factor β [TGF-β] family member) reduced muscle atrophy (27), and myostatin-targeting therapies have been proposed for treatment of cachexia and muscular dystrophy. Here, MSTN is linked to Cachexia.